Terms ending in 2032
Every in-force patent on Pharmacyclics, Inc.'s record whose computed term ends in 2032, whoever holds it now. Soonest term end first, then patent number.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Holder | Status | Expires | Confidence |
|---|---|---|---|---|---|
| US 8,377,946 | Pyrazolo[3,4-d]pyrimidine and Pyrrolo[2,3-d]pyrimidine Compounds as Kinase Inhibitors In force · High confidence | Pharmacyclics LLC | In force | High confidence | |
| US 9,273,051 | PYRAZOLO[3,4-d]PYRIMIDINE AND PYRROLO[2,3-d]PYRIMIDINE COMPOUNDS AS KINASE INHIBITORS In force · High confidence | Pharmacyclics LLC | In force | High confidence | |
| US 9,546,172 | PYRAZOLO[3,4-d]PYRIMIDINE AND PYRAZOLO[2,3-d]PYRIMIDINE COMPOUNDS AS KINASE INHIBITORS In force · High confidence | Pharmacyclics LLC | In force | High confidence | |
| US 9,408,816 | Method of Using Histone Deacetylase Inhibitors and Monitoring Biomarkers in Combination Therapy In force · High confidence | Pharmacyclics LLC | In force | High confidence | |
| US 8,883,199 | Administration Regime for N-HYDROXY-4-{2-[3-(N,N-DIMETHYLAMINOMETHYL)BENZOFURAN-2-Ylcarbonylamino]ETHOXY}BENZAMIDE Grace period ended Nov 11, 2026 · lapse expected · Low confidence | Pharmacyclics LLC | Grace period ended Nov 11, 2026 lapse expected | Low confidence | |
| US 9,138,436 | Inhibitors of Bruton's Tyrosine Kinase In force · High confidence | Pharmacyclics LLC | In force | High confidence |
6 of 6 patents shown. Soonest term end first, then patent number.
Updated Nov 19, 2026 · includes USPTO assignment data published Nov 18, 2026, status data published Nov 19, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.